My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.
My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.
